ClinicalTrials.gg
Status unknownNCT03639480Updated Aug 21, 2018

Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

A Phase 3 interventional study of Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg and Amlodipine 10mg+Valsartan 160mg in Hypertension and Hyperlipidemia, sponsored by HK inno.N Corporation. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2017, registered Aug 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
19 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Planned enrollment
92nd of 186
180 · median 180
Started
2017
with 8 others
Phase 3
69 of 187
2 open now
Registered
159th of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 92nd largest by planned enrollment of the 186 interventional ones that give a count, is one of 9 that started in 2017, is one of 69 in phase 3, and was the 159th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia

03

Conditions studied

  • Hypertension
  • Hyperlipidemia
04

Who can participate

Ages eligible
19 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 19 and 74 years
  • Diagnosed with essintial hypertension(average siSBP ≥ 140mmHg) accompanying hyperlipidemia(LDL-C ≥ 100mg/dL) and were on or off treatment at Visit 1(screening)
  • Decided to participate in the study and provided signed form voluntarily after receiving explanation of the objectives, methods, and effects of the study

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension defined as average siDBP ≥ 120mmHg or average siSBP ≥ 200mmHg at Visit 1(screening)
  • The difference in BPs between those measured at the reference arm at Visit 1(screening) was ≥ 10mmHg for siDBP or ≥ 20mmHg for siSBP
  • LDL-C > 250mg/dL or TG ≥ 400mg/dL at Visit 1(screening)
  • Secondary hypertension
  • Diagnosis of type 1 diabetes mellitus(DM) or uncontrolled DM(patients on insulin therapy or patients with ≥ 9%)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Test

    Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg

    Drug: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg

  • Active comparator
    Reference 1

    Amlodipine 10mg+Valsartan 160mg

    Drug: Amlodipine 10mg+Valsartan 160mg

  • Active comparator
    Reference 2

    Valsartan 160mg+Atorvastatin 40mg

    Drug: Valsartan 160mg+Atorvastatin 40mg

Interventions

  • DrugAmlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg

    Drug page: Amlodipine

    Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg

  • DrugAmlodipine 10mg+Valsartan 160mg

    Drug page: Amlodipine

    Amlodipine 10mg+Valsartan 160mg

  • DrugValsartan 160mg+Atorvastatin 40mg

    Drug page: Valsartan

    Valsartan 160mg+Atorvastatin 40mg

06

What researchers measure

Primary outcomes

  1. Change in siSBP

    Change in siSBP from baseline after 8 weeks of study treatment

    Time frame: baseline and 8 weeks

  2. Change in LDL-C

    Change in LDL-C from baseline after 8 weeks of study treatment

    Time frame: baseline and 8 weeks

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2017 (actual). Primary completion is estimated for Oct 2018, 12 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 12 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2018
First posted
Aug 21, 2018
StartActual
Oct 13, 2017
Primary completionEst.
Oct 2018
CompletionEst.
Oct 2018
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03639480
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Oct 13, 2017
Primary completion
Oct 2018 (estimated)
Completion
Oct 2018 (estimated)
Last update
Aug 21, 2018

Study contacts

Duk-Hyun Kang, Ph.D
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion